One More On QIDP List – Does It Help Wockhardt?

Regulatory Overhang An Impediment

Wockhardt has received QIDP designation in the US for its once-daily zidebactam-based combination antibiotic WCK 6777, taking to six its portfolio products with the status. But unless the FDA gives a clean sheet to the company’s major manufacturing units, this won't help US revenues 

Franklin
Will QIDP Status For Novel Antibiotic Help Wockhardt's US Revenues? • Source: Shutterstock

India's Wockhardt Ltd. has received qualified infectious disease product (QIDP) status from the US Food and Drug Administration (FDA) for its zidebactam-based combination antibiotic WCK 6777 to treat complicated urinary tract infections and complicated intra-abdominal infections, taking to six the total number of its products with this special designation.

The agency grants QIDP status to drugs effective against a set of multi-drug resistant pathogens identified by the Centers for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Manufacturing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.